ClinicalTrials.gg
RecruitingNCT07356076Updated Jan 27, 2026

The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases

An observational study in Lung Diseases, sponsored by University Hospital Olomouc. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by University Hospital Olomouc · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Lung Diseases with a site in Czechia — 10 open to participants now, 14 under way, 7 of them phase 3. Lung Diseases · Czechia.

Started
2025
with 3 others
Observational
2 of 29
1 open now
Primary completion
2027-12
later than 9 of 13 live
Registered
27th of 29
by date

Among the 29 studies in Lung Diseases with a site in Czechia, this one is one of 4 that started in 2025, is one of 2 observational ones, reaches primary completion later than 9 of the 13 other live ones, and was the 27th registered.

Lung Diseases

1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.

Browse Lung Diseases studies →

Open to participants now

10 of the 29 studies in Lung Diseases with a site in Czechia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Lung Diseases with a site in Czechia, or all of them as a file.
02

Study summary

The study titled "The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases" investigates the impact of using EIT as a non-invasive method to monitor the distribution of pulmonary ventilation and its relationship to standard spirometry in patients with various lung diseases. The main aim of this study is to investigate new approaches to the assessment of lung status and diagnosis of lung diseases.

Unlike spirometry, which has long been a well-known and important diagnostic tool in pulmonary medicine, and which provides valuable information about the volume and flow of inspired and expired air, EIT provides spatial information about the distribution of ventilation in real time and without the need for active patient cooperation. Research and practice have shown that spirometry is problematic in specific groups of patients, such as patients with tracheostomy or facial palsy. The technology should also enable detection of the disease in its early stages, when treatment is most effective.

300 participants in the experimental group and 100 participants in the control group will receive spirometry and electrical impedance tomography independent examination.

The primary endpoint of the study is to investigate the potential of EIT in respiratory medicine, specifically identifying the relationship between EIT and traditional spirometry. This effort is motivated by the need for novel noninvasive methods for the diagnosis and monitoring of respiratory diseases, especially in patients unable to undergo conventional spirometry, or in case of interventions requiring real-time feedback. The purpose of the research project in relation to these objectives is to bring new possibilities in the field of diagnosis and monitoring of lung diseases through EIT, which could lead to significant improvements in patient care.

Demographic and anthropometric data, including age, sex, body height, body weight, body mass index (BMI), chest circumference, and smoking history will be collected in all participants. These parameters will be used as covariates in the analysis to assess their impact on EIT-derived indicators and to improve normalization of EIT signals.

Additionally, the study aims to develop and validate a machine learning model, particularly a deep neural network, capable of predicting standard spirometric parameters (e.g., FEV1, FVC, PEF) based solely on EIT signals. This could allow for an accurate assessment of dynamic pulmonary volumes in cooperating patients who are unable to undergo conventional spirometry (e.g. patients with tracheostomy).

03

Conditions studied

  • Lung Diseases

Browse trials for

Keywords

  • Electrical Impedance Tomography
  • Spirometry
  • Lung Diseases
  • Lung Assessment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients of the Department of Pulmonary Diseases and Tuberculosis, University hospital Olomouc, and healthy controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older
  • Individuals diagnosed with any of the following lung diseases, as these are the primary focus of the study: , Asthma, Pulmonary fibrosis, Pneumonia, Patients with a history of COVID-19 infection showing residual pulmonary findings.
  • Additionally, healthy subjects will be enrolled to obtain normal standard values (with normal physical examination and no respiratory symptoms, 18-36 - cause EIT performance can be BMI dependent, Non-smokers or ex-smokers abstinent ≥12 months)
  • Ability to perform spirometry while seated, except for possible participants who are specifically part of a subgroup analysis where inability to perform spirometry is the condition which is studied.

Signing of an that has been approved by the ethics committee

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age
  • Severe cardiovascular disease
  • Pregnancy
  • Inability to express consent
  • Acute respiratory infection: Except for those recovering from pneumonia or COVID-19 within the study focus, participants with current respiratory infections will be excluded to avoid confounding effects on lung function tests
  • Inability to perform spirometry
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with lung diseases

    Adults aged 18 years and older Individuals diagnosed with any of the following lung diseases, as these are the primary focus of the study: Chronic obstructive pulmonary disease, Asthma, Pulmonary fibrosis, Pneumonia, Patients with a history of COVID-19 infection showing residual pulmonary findings. Ability to perform spirometry while seated, except for possible participants who are specifically part of a subgroup analysis where inability to perform spirometry is the condition which is studied. Signing of an informed consent that has been approved by the ethics committee

  • Healthy controls

    Adults aged 18 years and older Healthy subjects will be enrolled to obtain normal standard values (with normal physical examination and no respiratory symptoms, BMI 18-31 - cause EIT performance can be BMI dependent, Non-smokers or ex-smokers abstinent ≥12 months) Ability to perform spirometry while seated, except for possible participants who are specifically part of a subgroup analysis where inability to perform spirometry is the condition which is studied. Signing of an informed consent that has been approved by the ethics committee

06

What researchers measure

Primary outcomes

  1. Agreement between EIT-derived FEV1 and spirometry-derived FEV1

    Comparison of forced expiratory volume in 1 second predicted from EIT using a trained neural network with direct spirometry measurement. Metric: Mean Absolute Error (MAE), Bland-Altman limits of agreement, Pearson correlation coefficient (r)

    Time frame: At baseline visit (single measurement)

Secondary outcomes

  1. Forced Expiratory Volume in One Second (FEV1)

    FEV1 represents the volume of air that can be forcibly exhaled in the first second of a forced exhalation Measurements will be performed using calibrated spirometry. FEV1 is a standard measure of pulmonary function. Unit of Measure: Liters

    Time frame: At baseline visit (single measurement)

  2. Forced vital capacity (FVC)

    FVC represents the largest amount of air that can be forcefully exhaled from maximum inspiration. Unit of Measure: Liters

    Time frame: At baseline visit (single measurement)

  3. Peak Expiratory Flow (PEF)

    PEF represents the maximum flow achieved during forceful exhalation from maximum inspiration and is a reliable indicator of ventilation adequacy as well as airflow obstruction. Unit of Measure: Liters/minute

    Time frame: At baseline visit (single measurement)

  4. Estimated Lung Age (ELA)

    ELA is a calculation that estimates the age of a person's lungs based on their lung function, particurarly FEV1 (forced expiratory volume in one second), compared to normal lung function for their chronological age. Secondary objectives include comparison of regional ventilation patterns from EIT with spirometric flow-volume loop abnormalities, assessment of EIT-based estimated lung age, and determination of EIT's ability to track treatment response over time.

    Time frame: At baseline visit (single measurement)

  5. Forced Expiratory Volume in Three Seconds (FEV3)

    FEV3 represents the volume of air that can be exhaled during the first three seconds of forceful exhalation after maximum inspiration. Unit of Measure: Liters

    Time frame: At baseline visit (single measurement)

  6. Forced Expiratory Volume in Six Seconds (FEV6)

    FEV6 represents the volume of air that can be exhaled during the first six seconds of forceful exhalation after maximum inspiration Unit of Measure: Liters

    Time frame: At baseline visit (single measurement

  7. FEV1/FVC ratio

    FEV1/FVC is the ratio of forced expiratory volume in one second to forced vital capacity. Unit of Measure: Percentage

    Time frame: At baseline visit (single measurement

  8. Forced Expiratory Flow at 50 % of FVC (FEF50)

    FEF50 is the flow rate at the 50% point of the total volume (FVC) exhaled. Unit of Measure: Liters

    Time frame: At baseline visit (single measurement

  9. Forced Expiratory Flow at 75 % of FVC (FEF75)

    FEF75 is the flow rate at the 75% point of the total volume exhaled. Unit of Measure: Liters

    Time frame: At baseline visit (single measurement

07

Study locations

1 of 1 sites recruiting
  • Department of Pulmonary Diseases and Tuberculosis, University hospital Olomouc
    Olomouc, 77900, Czechia
    Recruiting
    • Samuel Genzor, Assoc. prof., MD, Ph.D. · Contactsamuel.genzor@fnol.cz · +420 588 443557
    • Jan Mizera, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 131 non-industry observational studies under Lung Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 25 months is below that.

Counting every sponsor, half of 153 studies reached it within 36 months; a quarter within 15 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 21, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07356076
Lead sponsor
University Hospital Olomouc
Collaborators
Brno University of Technology
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Nov 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion